ישראל - עברית - Ministry of Health

mediline ltd. - minoxidil 2 % - solution - minoxidil - androgenetic alopecia in males and females.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry - minoxidil 2 % - solution - minoxidil - for the treatment of alopecia androgenetica in both men and women.

ישראל - עברית - Ministry of Health

j-c health care ltd - minoxidil 20 mg/ml - solution - minoxidil - for the treatment of alopecia androgenetica in both men and women.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ישראל - עברית - Ministry of Health

pharmalogic ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the

ישראל - עברית - Ministry of Health

pharmalogic ltd - carboplatin 10 mg/ml - solution for infusion - carboplatin - carboplatin is used alone or in combination with other antineoplastic agents in the treatment of advanced ovarian carcinoma and metastatic small cell lung cancer.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.